FATE THERAPEUTICS INC FATE

Rank #2045 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (Ernst & Young, LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

35.5

P/E

-1.3

P/B

0.66

ROE

-50.6%

Op. Margin

-1542.6%

Debt Ratio

20%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -1.3x, P/B 0.66x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -50.6%. Ranks in the top 92% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 20%. Ranks in the top 13% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Poor

Revenue decline of 78.5% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2013	–	$-0.0B	$-0.0B	$-0.0B	–	-1009
2014	–	$-0.0B	$-0.0B	$-0.1B	–	-210
2015	–	$-0.0B	$-0.0B	$-0.1B	–	-197
2016	–	$-0.0B	$-0.0B	$0.1B	–	34
2017	–	$-0.0B	$-0.0B	$0.0B	–	235
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	-726.1	177
2019	$0.0B	$-0.0B	$-0.0B	$0.1B	-1025.9	191
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	-1415.4	292
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	-943.1	288
2022	$0.0B	$-0.1B	$-0.2B	$0.2B	-407.5	276
2023	$0.1B	$-0.3B	$-0.3B	$0.7B	-320.2	4
2024	$0.1B	$-0.2B	$-0.2B	$0.5B	-299.9	5
2025	$0.0B	$-0.2B	$-0.2B	$0.4B	-1542.6	20

← See the full screener